



## Successful Approaches to Implementation

Nicholas Coté, DO, CMIO  
NAIIS Summit 2017

### Intro

- *Who is MMC?*
- *Why Focus on Vaccines?*
- *Where were we?*
- *Where are we now?*
- *How did we get there?*
- *Issues/Solutions*
- *Closing*



## Who is MMC?

- *Physician Owned Multispecialty Group*
- *Since 1960's have been providing quality care to Middle TN*
- *>100 providers*
- *>600 employees*



## Why Focus on Vaccines?

- *2011- BCBS of TN prompted us to take the steps to become NCQA certified PCMH*
- *Vaccines are an “easy” item to measure and intervene upon for chronic care metrics*
- *Physician Leadership which saw the ROI for vaccines*



## Where were we?

2014:

- 65yo and older w/ Pneumovax: 86.5%
- Pneumovax >2 with Dx: 46.8%
- 18-64 w/ Tdap EVER: 63.2%

These were in addition to all the other PCMH metrics we started.



## Where were we?

- Zostavax (2015): Initially: 66.6% (>60) [27.9% Nationally<sup>1</sup>]
- Then focused to the ACIP Guideline and went for target range due to Medicare Payment Issues of 60-64: 55.8%
- Added Tetanus Q10 metric (18-64): 77%

1. [Surveillance of Vaccination Coverage Among Adult Populations — United States, 2014. MMWR 2016;65 \(ss01\);1–36.](#)



## Where are we now?

- Tetanus q10: 86% (+10%)
  - National Avg: 62.2%<sup>1</sup>
- Tdap EVER: 89% (+20.8%)
- Zoster Vaccine 60-64: 67% (+11.2%)
  - National Avg: 27.9% (pts >60yo) <sup>1</sup>
- Pneumovax >65: 93% (+6%)
  - National Avg: 71.9%<sup>2</sup>
- Pneumovax 18-64 w/ Dx: 78% (+31.2%)
  - National Avg: 33.5%<sup>2</sup>

1. [Surveillance of Vaccination Coverage Among Adult Populations — United States, 2014. MMWR 2016;65 \(ss01\);1–36.](#)
2. <https://www.cdc.gov/vaccines/imz-managers/coverage/adultvaxview/data-reports/general-population/dashboard/2015.html>



## Another Metric

2017:

Added HPV Vaccine: Females: 31%

Current Rates (with 4mo of work) 38% (+7%)

- National Rates 40.2%<sup>1</sup>
- TN Rates: 20.1%<sup>2</sup>

1. [Surveillance of Vaccination Coverage Among Adult Populations — United States, 2014. MMWR 2016;65 \(ss01\);1–36.](#)
2. <https://www.cdc.gov/vaccines/imz-managers/coverage/adultvaxview/data-reports/general-population/dashboard/2015.html>



## How did we get there?

- Nurses!!!
- “Automate” the process
- Use Population Health Tool
  - Leverage EHR
  - Use “Bolt-on” product if needed



## Standardize It!

- DEVELOP:
  - Clinicians: Standardize Orders for Vaccination in Ambulatory setting
  - Teach Protocols to Nursing/Care Teams
- EMPOWER:
  - Standardized orders = Standing orders for Nursing staff
  - Make it the Responsibility of Nursing staff
- INCENTIVIZE:
  - Make their annual Salary Adjustment &/o bonus contingent upon this objective metric
  - Public Shaming of Lower Performing Teams



## Challenges/Solutions

- *Zostavax: in >65yo: Cost high and it is Medicare Part D.*
  - CMS Needs to make coverage Part B and **preventative**
- *Tdap/Tetanus >65: Not covered by CMS.*
  - CMS Needs to make coverage Part B and **preventative**

*These solutions will Increase Ambulatory Vaccine Rates*



## Challenges/Solutions

- *HPV: Issue is the mis-information regarding it.*
  - Market it as a CANCER vaccine like was done with Hepatitis B vaccine
  - Also, insurers need to make this a “Free” Vaccine.

*These solutions will Increase Ambulatory Vaccine Rates*



## Challenges/Solutions

- *Issue: Cost fluctuation for vaccines and disparity between cost and reimbursement with payors.*
- *This is a significant barrier for Ambulatory Centers*
  - *Was a big issue initially with Zostavax*
    - Stable vaccine costs for certain periods of time
    - Mandates for reliable payment by payors



## Closing

- *Providers won't remember*
- *Utilize the Nursing staff to close these gaps*
- *Get UTD prior to Medicare*
- *Measure and Report back to Provider teams*

*Motto: The Patient's arms should be sore by the time provider walks into the room*

